Section Arrow
PHVS.NASDAQ
- Pharvaris NV
Quotes are at least 15-min delayed:2025/11/17 02:19 EST
Regular Hours
Last
 23.55
-0.71 (-2.93%)
Day High 
25.045 
Prev. Close
24.26 
1-M High
26.0557 
Volume 
360.94K 
Bid
24
Ask
37.95
Day Low
23.48 
Open
24.36 
1-M Low
20.65 
Market Cap 
1.56B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 22.83 
20-SMA 22.81 
50-SMA 23.19 
52-W High 26.33 
52-W Low 11.51 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.09/-3.33
Enterprise Value
1.56B
Balance Sheet
Book Value Per Share
5.57
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/17 02:19 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel smallmolecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.